The startup develops transdermal psilocin neuromodulation therapy to treat musculoskeletal disorders by alleviating pain and promoting nervous tissue repair. This targeted approach enhances motor function performance and provides a new treatment option for various psychiatric and neurological conditions.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Musculoskeletal disorders and various psychiatric and neurological conditions often result in chronic pain and impaired motor function, creating a need for innovative therapeutic interventions. Current treatments may have limited efficacy or undesirable side effects, highlighting the need for alternative approaches to alleviate pain and promote nervous tissue repair.
Solution
LongTermGevity is developing a transdermal psilocin neuromodulation therapy designed to address musculoskeletal disorders by targeting pain relief and nervous tissue regeneration. Their approach involves delivering psilocin through the skin, potentially offering a more targeted and controlled method of neuromodulation. By directly influencing the nervous system, the therapy aims to enhance motor function performance and provide a novel treatment option for individuals suffering from a range of conditions. The transdermal delivery system may also improve patient compliance and reduce systemic side effects compared to traditional oral or injectable medications.
Target Audience
The primary target audience includes individuals suffering from musculoskeletal disorders, chronic pain, and neurological conditions, as well as healthcare providers seeking innovative treatment options.
Features
- Transdermal delivery system for targeted psilocin administration.
- Neuromodulation therapy designed to alleviate pain associated with musculoskeletal disorders.
- Promotes nervous tissue repair and regeneration.
- Aims to enhance motor function performance.